(Nasdaq: TNXP) announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for ...

The FDA has accepted the NDA for TNX-102 SL (cyclobenzaprine HCL sublingual tablets) for the management of fibromyalgia.

Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins. The FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action ...

a non-opioid, centrally acting analgesic designed for fibromyalgia management. The FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date in its Day 74 Letter ...

Tonix Pharmaceuticals (TNXP) said it has received a target action data of Aug. 15, 2025, for the application of its ...

TNX-102 SL is a non-opioid, centrally-acting analgesic administered at bedtime for the treatment of fibromyalgia. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA ...

If the NDA is accepted, Tonix said the FDA could commit to a decision on approval in 2025, which means TNX-102 SL could be on the market as early as next year, giving fibromyalgia sufferers a ...

Opioids are present in around 60% of drug-induced deaths in Australia. A medicine called naloxone is available for Australians to take home in case of opioid overdose. Here’s how it works ...

Tonix Pharmaceuticals (NASDAQ: TNXP) announced that the FDA has set a Prescription Drug User Fee Act (“PDUFA”) goal date of Aug. 15, 2025, for a de ...

GRAND RAPIDS, Mich. (WOOD) — Health officials warn that extremely cold weather could render lifesaving overdose reversal drug Narcan ineffective. Nationally, overdose deaths declined by 14% ...